[Long GnRH agonist vs. GnRH antagonist protocol in randomized controlled trial in unselected patients--hormonal and cycle characteristics--pilot study].

Streda R, Mardesic T, Sobotka V, Tosner J

Ceska gynekologie1 Apr 2009Cited by 3 (Europe PMC)

PMID19514651PepBankPUB-19514651

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In unselected patients, day 5 estradiol was 385 +/- 293 pg/ml with cetrorelix versus 269 +/- 243 with triptorelin.
In plain wordsIn unselected patients, day 5 estradiol was higher with cetrorelix than triptorelin; significance was not stated.
Peptide
Cetrorelix
Outcome
IncreaseEstradiol on day 5
Study
n = 40
Comparator
Triptorelin 0.1 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mgAs given in this study (human).
Measurements
Estradiol on day 5, mean
385 pg/ml
cetrorelix group; SD 293
Estradiol on day 5, mean
269 pg/ml
triptorelin group; SD 243
Source sentences
Summary
We proved E2 on day 5 (pg/ml) 269 +/- 243 vs. 385 +/- 293
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized prospective pilot study.
Summary · context
From January 2006 to June 2006 we randomized 40 unselected patients into GnRH agonist (triptorelin 0.1 mg) and GnRH antagonist (cetrorelix 0.25 mg) group.
Summary · context
We randomized 21 patients in GnRH agonist and 19 patients in GnRH antagonist group.
Summary · context
in GnRH agonist vs. GnRH antagonist group, resp.
Report a problemFND-1951465101
02HumanRandomized controlled trialEfficacy outcome
In unselected patients, day 5 LH was 2.8 +/- 1.4 IU/l with cetrorelix versus 1.7 +/- 1.2 with triptorelin.
In plain wordsIn unselected patients, day 5 LH was higher with cetrorelix than triptorelin; significance was not stated.
Peptide
Cetrorelix
Outcome
IncreaseLH on day 5
Study
n = 40
Comparator
Triptorelin 0.1 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mgAs given in this study (human).
Measurements
LH on day 5, mean
2.8 IU/l
cetrorelix group; SD 1.4
LH on day 5, mean
1.7 IU/l
triptorelin group; SD 1.2
Source sentences
Summary
LH on day 5 (IU/l) 1.7 +/- 1.2 vs. 2.8 +/- 1.4
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized prospective pilot study.
Summary · context
From January 2006 to June 2006 we randomized 40 unselected patients into GnRH agonist (triptorelin 0.1 mg) and GnRH antagonist (cetrorelix 0.25 mg) group.
Summary · context
We randomized 21 patients in GnRH agonist and 19 patients in GnRH antagonist group.
Summary · context
in GnRH agonist vs. GnRH antagonist group, resp.
Report a problemFND-1951465102
03HumanRandomized controlled trialEfficacy outcome
In unselected patients, hCG-day estradiol was lower with cetrorelix: 1397 +/- 1076 versus 1548 +/- 1167 pg/ml (p < 0.05).
In plain wordsIn unselected patients, estradiol on the hCG day was lower with cetrorelix than triptorelin.
Peptide
Cetrorelix
Outcome
DecreaseEstradiol on hCG day
Study
n = 40
Comparator
Triptorelin 0.1 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mgAs given in this study (human).
Measurements
Estradiol on hCG day, mean
1397 pg/ml
cetrorelix group; SD 1076
Estradiol on hCG day, mean
1548 pg/ml
triptorelin group; SD 1167
Source sentences
Summary
E2 on the day of hCG administration (pg/ml) 1548 +/- 1167 vs. 1397 +/- 1076 (p < 0.05)
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized prospective pilot study.
Summary · context
From January 2006 to June 2006 we randomized 40 unselected patients into GnRH agonist (triptorelin 0.1 mg) and GnRH antagonist (cetrorelix 0.25 mg) group.
Summary · context
We randomized 21 patients in GnRH agonist and 19 patients in GnRH antagonist group.
Summary · context
in GnRH agonist vs. GnRH antagonist group, resp.
Report a problemFND-1951465103
04HumanRandomized controlled trialEfficacy outcome
In unselected patients, hCG-day LH did not differ significantly: 1.4 +/- 1.1 IU/l with cetrorelix versus 2.2 +/- 1.9 with triptorelin.
In plain wordsIn unselected patients, LH on the hCG day did not differ significantly between cetrorelix and triptorelin.
Peptide
Cetrorelix
Outcome
No significant changeLH on hCG day
Study
n = 40
Comparator
Triptorelin 0.1 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mgAs given in this study (human).
Measurements
LH on hCG day, mean
1.4 IU/l
cetrorelix group; SD 1.1
LH on hCG day, mean
2.2 IU/l
triptorelin group; SD 1.9
Source sentences
Summary
LH on the day of hCG administration (IU/l) 2.2 +/- 1.9 vs. 1.4 +/- 1.1 (ns)
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized prospective pilot study.
Summary · context
From January 2006 to June 2006 we randomized 40 unselected patients into GnRH agonist (triptorelin 0.1 mg) and GnRH antagonist (cetrorelix 0.25 mg) group.
Summary · context
We randomized 21 patients in GnRH agonist and 19 patients in GnRH antagonist group.
Summary · context
in GnRH agonist vs. GnRH antagonist group, resp.
Report a problemFND-1951465104
05HumanRandomized controlled trialEfficacy outcome
In unselected patients, endometrial thickness did not differ significantly: 9.2 +/- 0.9 mm with cetrorelix versus 10.6 +/- 1.8 with triptorelin.
In plain wordsIn unselected patients, uterine lining thickness did not differ significantly between cetrorelix and triptorelin.
Peptide
Cetrorelix
Outcome
No significant changeEndometrial thickness
Study
n = 40
Comparator
Triptorelin 0.1 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mgAs given in this study (human).
Measurements
Endometrial thickness, mean
9.2 mm
cetrorelix group; SD 0.9
Endometrial thickness, mean
10.6 mm
triptorelin group; SD 1.8
Source sentences
Summary
endometrial thickness (mm) 10.6 +/- 1.8 vs. 9.2 +/- 0.9 (ns)
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized prospective pilot study.
Summary · context
From January 2006 to June 2006 we randomized 40 unselected patients into GnRH agonist (triptorelin 0.1 mg) and GnRH antagonist (cetrorelix 0.25 mg) group.
Summary · context
We randomized 21 patients in GnRH agonist and 19 patients in GnRH antagonist group.
Summary · context
in GnRH agonist vs. GnRH antagonist group, resp.
Report a problemFND-1951465105
06HumanRandomized controlled trialEfficacy outcome
In unselected patients, total FSH dose was lower with cetrorelix: 1513 +/- 357 versus 1865 +/- 517 IU (p < 0.001).
In plain wordsIn unselected patients, total FSH dose was lower with cetrorelix than triptorelin.
Peptide
Cetrorelix
Outcome
DecreaseTotal FSH dose
Study
n = 40
Comparator
Triptorelin 0.1 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mgAs given in this study (human).
Measurements
Total FSH dose, mean
1513 IU
cetrorelix group; SD 357
Total FSH dose, mean
1865 IU
triptorelin group; SD 517
Source sentences
Summary
total dose of FSH (IU) 1865 +/- 517 vs. 1513 +/- 357 (p < 0.001)
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized prospective pilot study.
Summary · context
From January 2006 to June 2006 we randomized 40 unselected patients into GnRH agonist (triptorelin 0.1 mg) and GnRH antagonist (cetrorelix 0.25 mg) group.
Summary · context
We randomized 21 patients in GnRH agonist and 19 patients in GnRH antagonist group.
Summary · context
in GnRH agonist vs. GnRH antagonist group, resp.
Report a problemFND-1951465106
07HumanRandomized controlled trialEfficacy outcome
In unselected patients, FSH stimulation was shorter with cetrorelix: 7.8 +/- 1.2 versus 9.3 +/- 1.6 days (p < 0.001).
In plain wordsIn unselected patients, FSH stimulation was shorter with cetrorelix than triptorelin.
Peptide
Cetrorelix
Outcome
DecreaseFSH stimulation duration
Study
n = 40
Comparator
Triptorelin 0.1 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mgAs given in this study (human).
Measurements
Duration of FSH stimulation, mean
7.8 days
cetrorelix group; SD 1.2
Duration of FSH stimulation, mean
9.3 days
triptorelin group; SD 1.6
Source sentences
Summary
duration of FSH stimulation (days) 9.3 +/- 1.6 vs. 7.8 +/- 1.2 (p < 0.001) in GnRH agonist vs. GnRH antagonist group, resp.
3 context sentences(design, population, supporting numbers)
Summary · context
Randomized prospective pilot study.
Summary · context
From January 2006 to June 2006 we randomized 40 unselected patients into GnRH agonist (triptorelin 0.1 mg) and GnRH antagonist (cetrorelix 0.25 mg) group.
Summary · context
We randomized 21 patients in GnRH agonist and 19 patients in GnRH antagonist group.
Report a problemFND-1951465107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.